Seelos Therapeutics, Inc.

SEELQ Healthcare Biotechnology

Seelos Therapeutics, Inc.’s revenue for fiscal 2023 (year ended December 2023) was $2.2 million. Revenue growth for three consecutive years, operating cash flow growth for three.

0.00 0.00 NaN
Market cap
$700.0K
P/E
0.0×
Fwd P/E
−1.0×
Dividend yield
—
F-score
n/a
Altman Z
−96.86
Beneish M
n/a
Dividend safety
n/a
Older periods Sep '23 Dec '23 Mar '24 Jun '24
P/E ratio

+8 more quarters

0.00 0.00 0.00 0.03
P/S ratio
13.59 3.07 3.85 0.77
P/FCF ratio
0.00 0.00 0.00 0.00
P/Operating CF
(4.55) (3.54) (1.64) (1.59)
P/B ratio
0.00 0.00 0.00 0.00
Price to Tangible BV
0.00 0.00 0.00 0.00
EV/Sales
12.92 2.30 4.25 1.27
EV/EBITDA
0.00 0.00 0.00 0.00
EV/Operating CF
(0.71) (0.21) (0.46) (0.19)
EV/FCF
(0.71) (0.21) (0.46) (0.19)
Quick Ratio
0.08 0.10 0.04 0.02
Current Ratio
0.18 0.14 0.10 0.08
Net Debt/EBITDA
0.10 0.37 0.09 0.09
Debt/Assets
20.96% 0.00% 0.00% 0.00%
Debt/Equity
(0.04) 0.00 0.00 0.00
Asset Turnover
0.08 0.16 0.14 0.28
Operating CF/Net income
(0.55) 0.35 1.74 (0.57)
Capex/Depreciation
0.00 — 0.00 0.00
Interest Coverage
(300.07) (421.63) (263.26) (136.48)
Research and Development Expense of Revenue
2,468.47% 906.28% 608.81% 256.91%
Selling, General and Administrative Expense of Revenue
735.71% 420.52% 536.96% 677.93%
Intangible Assets out of Total Assets
0.00 0.00 0.00 0.00
Share Based Compensation of Revenue
239.90% 147.63% 164.94% 231.91%
Graham Net Nets
(1.16) (4.96) (4.36) (18.18)
Graham Number
5,713.09 4,399.43 2,003.48 0.00
Earnings Yield
(225.97%) (556.60%) (731.20%) 3,246.71%
Free Cash Flow Yield
(134.22%) (353.67%) (239.50%) (857.17%)
Revenue per Share
11.53 17.05 5.70 2.40
Operating CF per Share
(163.32) (49.90) (45.69) (6.21)
Capex per Share
0.00 0.00 0.00 0.00
Free Cash Flow per Share
(163.32) (49.90) (45.69) (6.21)
Cash per Share
73.41 78.22 5.16 1.88
Shareholders Equity per Share
(863.98) (874.93) (325.83) (179.65)
Interest Debt per Share
0.00 0.00 0.00 0.00
Book value per Share
(863.98) (874.93) (325.83) (179.65)
Free Cash Flow
(5.75) (1.91) (4.64) (0.97)
Working Capital
(29.14) (33.52) (33.17) (28.18)
Net Current Asset Value
(30.44) (33.52) (33.17) (28.18)
EV/EBIT
0.00 0.00 0.00 0.00
Capex to Sales
0.00 0.00 0.00 0.00
Price to Operating Income
0.00 0.00 0.00 0.00
Other line items
Average Receivables
0.45 0.58 0.88 0.31
Average Payables
7.64 10.01 10.62 11.06
Average Assets
23.36 14.08 13.63 7.14
Average Common Equity
(11.27) (22.06) (26.88) (37.66)

Fold the line items

Columns are period end dates